医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Herbalife Appoints Filipino Doctor to Its Nutrition Advisory Board

2016年01月04日 PM12:00
このエントリーをはてなブックマークに追加


 

HONG KONG

Global nutrition company, Herbalife welcomes Dr. Francis Gregory Samonte, an expert in pediatric neurology, to become the first Filipino appointed to its prestigious Nutrition Advisory Board (NAB), effective January 1, 2016.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160103005079/en/

A photo of Dr Francis Gregory Samonte (Photo: Business Wire)

A photo of Dr Francis Gregory Samonte (Photo: Business Wire)

The Herbalife Nutrition Advisory Board is comprised of leading experts from around the world in the fields of nutrition and health who inform, educate and train Independent Herbalife Members on the principles of nutrition, physical activity and healthy lifestyle.

Samonte’s appointment further strengthens the Herbalife Nutrition Advisory Board members to 30. His addition also reflects further expansion of nutrition and health experts from Asia Pacific in the Nutrition Advisory Board who will play a central role in raising public awareness and leading educational programs on balanced nutrition and healthy active lifestyle in 15 countries across the region as part of Herbalife’s Asia Pacific Wellness Tour initiative.

Samonte is among the Philippines’ premier experts in pediatric neurology, and is currently based in Manila. He graduated from De La Salle University College of Medicine in 1995, and has since studied at institutes including John Hopkins University and Harvard Medical School, USA. He was a recipient of the Chairman’s Achievement Award, Department of Pediatrics, University of Louisville, Kentucky, and his affiliations include the Philippines Medical Association.

In tandem with his distinguished career in medicine, Samonte is active in supporting charities, notably through being a member of the Board of Directors of Community Based Resources in Zambales.

Herbalife Nutrition Advisory Board

The board is chaired by David Heber, M.D., Ph.D., Founding Director of the Center for Human Nutrition at the University of California, Los Angeles (UCLA)*, who was recently in Manila for Herbalife’s fourth Asia Pacific Wellness Tour, which included an obesity seminar given to Filipino medical practitioners. Other members of the NAB include Dr. Lou Ignarro, a Nobel** laureate in Physiology or Medicine in 1998 for his discovery of nitric oxide’s health benefits; Dr. Gary Small, a specialist in brain health and aging, who has received numerous awards and honors, including the “Senior Investigator Award” from the American Association for Geriatric Psychiatry.

* The University of California, as a matter of policy, does not endorse specific products or services. Dr. Heber’s credentials as a professor are for identification purposes only.

**The Nobel Foundation has no affiliation with Herbalife and does not review, approve or endorse Herbalife® products.

About Herbalife

Herbalife (NYSE:HLF) is a global nutrition company that sells weight-management, nutrition and personal care products intended to support a healthy lifestyle. Herbalife products are sold in more than 90 countries to and through a network of Independent Herbalife Members. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife’s website contains financial and other information about the company at www.herbalife.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160103005079/en/

CONTACT

Media Enquiries:
Herbalife Asia Pacific
Daliea
Mohamad-Liauw, +852-3589-2643
Vice President, Corporate
Communications
dalieal@herbalife.com
or
Herbalife
Philippines
Barbs A. Soliven, 632-555-2828
Corporate
Communications Manager
barbettes@herbalife.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024